INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences Holdings Corporation announced that Bob Davis, Executive Vice President and President of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference. The presentation is scheduled for June 16, 2026, at 3:00 PM ET. A live webcast of the event will be accessible on the company's investor relations website.

Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, at 10:30 AM ET. A live webcast of the event will be accessible on the company's investor relations website under 'EVENTS & PRESENTATIONS'.

Integra LifeSciences Holdings Corporation held its 2026 Annual Meeting of Stockholders on May 7, 2026. Stockholders approved Amendment No. 3 to the 2003 Equity Incentive Plan, increasing the number of shares available for awards by 3,550,000. Additionally, all director nominees were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor, and the compensation of named executive officers was approved on an advisory basis.

Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the BofA Securities 2026 Health Care Conference. The presentation is scheduled for May 12, 2026, at 4:20 PM PT. A live webcast of the event will be accessible via the company's investor relations website.

Integra LifeSciences reported Q1 2026 net revenue of $391.9 million, an increase from $382.7 million in Q1 2025. The company significantly narrowed its net loss to $4.6 million, or $(0.06) per share, compared to a net loss of $25.3 million, or $(0.33) per share, in the prior year period. Additionally, Integra LifeSciences recognized an $18.7 million receivable for IEEPA tariff refunds and detailed an amendment to its Senior Credit Facility in June 2025, which modified Consolidated Total Leverage Ratio covenants. The company also updated its segment names to Specialty Surgery and Tissue Reconstruction.

Integra LifeSciences Holdings Corporation reported its first quarter 2026 financial results, with revenues reaching $391.9 million, an increase of 2.4% on a reported basis and 1.3% organically year-over-year. The company saw an improvement in GAAP diluted EPS to $(0.06) from $(0.33) in the prior year, while adjusted diluted EPS rose to $0.54 from $0.41. Integra LifeSciences reaffirmed its full-year 2026 revenue guidance and raised its adjusted EPS guidance to a range of $2.40 to $2.50, citing benefits from IEEPA tariffs and improved operational performance.

Integra LifeSciences announced the appointment of Stuart M. Essig as President and Chief Executive Officer, effective May 1, 2026. Mr. Essig, who previously served as CEO from 1997 to 2012 and as chairman since 2012, succeeds Mojdeh Poul. The company also appointed Michael McBreen as Chief Commercial Officer, a newly created role, to strengthen revenue growth and customer focus. The Board expressed full confidence in Mr. Essig's leadership, stating this is a long-term appointment.

Integra LifeSciences reported Q1 2026 revenues of $391.9 million, a 2.4% reported increase and 1.3% organic growth year-over-year. GAAP diluted EPS was $(0.06), an improvement from $(0.33) in the prior year, while adjusted diluted EPS rose to $0.54 from $0.41. The company reaffirmed its full-year 2026 revenue guidance of $1.662 billion to $1.702 billion and updated its adjusted EPS guidance from $2.30-$2.40 to $2.40-$2.50. Additionally, Stuart Essig was appointed President and CEO, and Michael McBreen was promoted to Chief Commercial Officer, as noted in a separate release.

Integra LifeSciences Holdings Corporation's subsidiaries entered into amendments for their $150 million accounts receivable securitization facility on April 10, 2026. These amendments, including Amendment No. 8 to the Receivables Financing Agreement and Amendment No. 1 to the Purchase and Sale Agreement, update the existing facility. The facility, originally established in December 2018, continues to provide liquidity and funding for the company's ongoing business needs and helps reduce outstanding revolving borrowings.